Summary: A method for quantitatively predicting the hepatic clearance of drugs by UDP-glucuronosyltransferases (UGTs) from in vitro data has not yet been established. We examined the relationship between in vitro and in vivo intrinsic clearance by rat hepatic UGTs using 10 drugs. For these 10 drugs, the in vitro intrinsic clearance by UGTs (CL int, in vitro ) measured using alamethicin-activated rat liver microsomes was in the range 0.104500 ml/min/kg. Microsomal binding (f u, mic ) was determined to be in the range 0.290.95 and the unbound intrinsic clearance (CL uint, in vitro ) to be in the range 0.119600 ml/min/kg. The contribution of rat hepatic glucuronidation to drug elimination was 12.0%76.6% and in vivo intrinsic clearance by UGTs was 5.79000 ml/min/kg. To evaluate the discrepancy between the in vitro and in vivo values, a scaling factor was calculated (CL int, in vivo /CL int, in vitro ); the values were found to be in the range 0.89110. The average fold error of the scaling factor values incorporating f u, mic was closer to unity than that without f u, mic . The scaling factor values incorporating f u, mic were <10 in 8/10 drugs and <2 in 6/10 drugs, indicating a small discrepancy between in vitro and in vivo values. Thus, using alamethicin-activated liver microsomes, incorporating f u, mic into CL int, in vitro , and considering the contribution of glucuronidation may enable us to quantitatively predict in vivo hepatic glucuronidation from in vitro data.
Introduction
Polar groups, such as hydroxyl and carboxyl groups, are often introduced into drug candidates during the discovery stage in an effort to improve metabolic stability or reduce drug-drug interaction mediated by cytochrome P450 ¤CYP¥; however, most drugs may still be metabolized via glucuronidation and/or sulfation. In particular, glucuronidation plays an important role in drug clearance, as many drugs are metabolized by hepatic UDP-glucuronosyltransferases ¤UGTs¥ before being eliminated from the body. 1¥ Thus, hepatic glucuronidation plays an important role in determining the pharmacokinetics of drugs. However, a suitable method for quantitatively predicting hepatic clearance by UGTs from in vitro data has not yet been established.
For drugs metabolized by CYPs, it is possible to quantitatively predict hepatic clearance from data relating to in vitro intrinsic clearance by CYPs. These data are generated in experiments using human liver microsomes and are based on physiological models and clearance concepts.
2®4¥
Incorporation of the effects of microsomal binding ¤f u, mic ¥ is reported to be useful for improving the accuracy of predicting in vivo intrinsic clearance in humans as it enables the use of in vitro data to successfully predict clearance in humans. 5¥ In addition, successful predictions of human hepatic clearance have been made from human in vitro intrinsic clearance data corrected using animal scaling factors ¤the ratio of in vivo intrinsic clearance to in vitro intrinsic clearance¥. 6¥ Estimations based on in vitro microsomal data generally underpredict the clearance of glucuronidated drugs, with a few studies reporting underpredictions of between 10-and 30-fold. 7®9¥ This in vitro underprediction is thought to occur because the UGT active site is located on the luminal side of the endoplasmic reticulum, making drug access difficult. 10¥ To overcome the problem of underprediction when using in vitro data, detergents and pore-forming agents ¤e.g., alamethicin¥ have been added to the incubation mixture, resulting in increased glucuronidation activity in vitro.
10®12¥ Indeed, the glucuronidation of diclofenac in liver microsomes is increased by the addition of alamethicin, and the predictions of clearance from in vitro data using activated human liver microsomes is consistent with the observed clearance. 13¥ Although experimental conditions for the activation of UGTs have been investigated extensively, an accurate method for predicting in vivo glucuronidation from in vitro data has not been established. In vitro-in vivo correlation in humans has only been investigated for a limited number of drugs, due in part to the relatively few drugs for which human pharmacokinetic parameters, such as the total plasma clearance after intravenous dosing and the influence of glucuronidation on elimination, are known. Although rats are useful model animals for acquiring pharmacokinetic parameters, only a limited number in vitro-in vivo correlation studies for glucuronidation in rats have been conducted.
Mistery and Houston 9¥ reported in vitro-in vivo correlation in rats using structurally analogous compounds ¤naloxone, morphine, and buprenorphine¥. The in vitro intrinsic clearance of these compounds by UGTs ¤CL int, in vitro ¥ was 10-to 30-fold lower than the in vivo intrinsic clearance ¤CL int in vivo ¥. However, the glucuronidation clearance predicted from in vitro data was only 3-fold lower than the observed clearance in the case of troglitazone. 14¥ In an attempt to increase prediction accuracy, Izumi et al.
14¥
evaluated CL int, in vitro of troglitazone using alamethicinactivated rat liver microsomes and incorporating f u, mic in CL int, in vitro to avoid in vitro underestimation of CL int, in vitro due to the binding of microsomal protein to troglitazone. The contribution of glucuronidation to clearance was also considered to avoid overestimation of in vivo glucuronidation clearance. However, these studies in rats were not conducted under the same conditions, and in vitro-in vivo correlation of rat hepatic glucuronidation has been demonstrated for only a few compounds. Therefore, it remains unclear whether glucuronidation clearance can be predicted from in vitro data.
The aims of the present study were to investigate the correlation between CL int, in vitro and CL int, in vivo in rats and to clarify whether in vivo glucuronidation can be predicted using alamethicin-activated microsomes by incorporating f u, mic in CL int, in vitro and considering the overall contribution of glucuronidation to clearance.
Methods
Materials: Ezetimibe, naloxone, zidovudine, and their glucuronide derivatives ¤except for naloxone¥ were purchased from Toronto Research Chemicals ¤North York, ON, Canada¥. Gemfibrozil, diclofenac, naproxen, UDP-glucuronic acid ¤UDPGA¥, and naloxone-3-glucuronide were purchased from Sigma-Aldrich ¤St. Louis, MO, USA¥, and telmisartan and raloxifene from LKT Laboratories ¤St. Paul, MN, USA¥. Compounds A and B and their glucuronides were synthesized by Astellas Pharma Inc. ¤Tokyo, Japan¥. Pooled male Sprague-Dawley rat liver microsomes ¤RLMs; n © 400¥ were purchased from Xenotech LLC ¤Lenexa, KS, USA¥. All other chemicals and reagents were of analytical grade and were readily available from commercial sources.
Animals: Male Sprague-Dawley ¤SD¥ rats ¤aged 8®9 weeks¥ were purchased from Charles River Laboratories ¤Yokohama, Japan¥. All animals were maintained under standard conditions with a 12 h/12 h light/dark cycle and were treated humanely. Food and water were available ad libitum. The studies were conducted in accordance with the guidelines of Astellas Pharma Inc.
Determination of glucuronidation clearance of substrates using rat liver microsomes: Each substrate was dissolved in 50% acetonitrile to a give a concentration of 1 mM and was then incubated in a reaction mixture consisting of liver microsomes ¤final concentration © 0.1, 0.2, or 1 mg/ml¥ and UDPGA ¤final concentration © 2 mM¥ in the presence of 50 mM Tris-HCl buffer ¤pH 7.4¥, 8 mM magnesium chloride, and alamethicin at a final concentration of 50 µg/mg microsomal protein. Each substrate solution was added to give a final substrate concentration of 2 µM ¤the acetonitrile concentration in the reaction mixture was 0.1%¥. After preincubation at 37ôC, UGT cofactor solution containing UDPGA was added to initiate the enzyme reaction. The reaction was terminated at pre-determined time points by mixing the reaction mixture with a 2-fold volume of chilled acetonitrile, followed by centrifugation at 15,000 g for 5 min at 4ôC. An aliquot of the supernatant was injected into a liquid chromatographytandem mass spectrometer ¤LC-MS/MS¥ apparatus to measure the concentration of the unchanged compound. CL int, in vitro values were calculated based on the rate of substrate disappearance within the RLMs.
6¥
For telmisartan and zidovudine, no definite decrease in the unchanged form was detected in the incubation mixture. Therefore, the intrinsic clearance of telmisartan was determined based on the rate of glucuronide formation at a substrate concentration of 1 µM. The method used to determine the intrinsic clearance for zidovudine is described below. The CL int, in vitro values per milligram of microsomal protein calculated from in vitro metabolism experiments were expressed per kilogram of body weight by taking into consideration the microsomal protein content per gram of liver and the liver weight per kilogram of body weight ¤Table 1¥.
Kinetics of glucuronidation of zidovudine in RLMs: We determined the Michaelis-Menten kinetics for zidovudine glucuronidation in the presence and absence of 2% bovine serum albumin ¤BSA¥. The components of the reaction mixture were as described above, except for the presence of 2% BSA. The incubation time was 30 min. The rate of zidovudine glucuronide formation was calculated at each substrate concentration. Kinetic constants ¤Km and Vmax¥ relating to zidovudine glucuronidation in RLMs in the presence and absence of 2% BSA were generated by fitting the experimental data to the Michaelis-Menten equation. CL int, in vitro was determined as Vmax/Km, which was corrected using rat physiological parameters.
Determination of blood-to-plasma concentration ratios ¤R b ¥: Blood obtained from male SD rats was used to determine R b values. The chemical compounds were added individually to blood samples and then incubated at 37ôC for 20 min. After incubation, plasma was obtained by centrifuging the samples at 1500 g for 5 min. The concentration of each substrate in the plasma and blood samples was determined using LC-MS/MS. R b was calculated using the following equation:
where C p is the concentration in the plasma and C b the concentration in the blood. Determination of plasma protein binding: Plasma protein binding was determined using ultracentrifugation, as previously described. 15¥ Briefly, a 1000-µl aliquot of plasma was first mixed with each substrate ¤final concentration © 1000 ng/ml¥, and then a 200-µl aliquot of the plasma-substrate mixture was transferred to a centrifuge tube and ultracentrifuged at 436,000 g for 120 min at 37ôC. After centrifugation, 20 µl of the upper layer was removed by siphoning and the concentration of the unchanged compound in the upper layer was determined using LC-MS/MS. The remaining plasma-substrate mixture was incubated for 120 min at 37ôC for determination of the total unchanged compound concentration by LC-MS/MS. The unbound fraction of plasma ¤f p ¥ was calculated using the following equation:
Determination of unbound fractions in incubation mixture: Microsomal binding was determined using ultracentrifugation. Briefly, a 1000-µl aliquot of microsomal mixture ¤microsomal protein concentration © 0.2 mg/ml, except for ezetimibe ª0.1 mg/ml«, and compound B and naproxen ª1.0 mg/ml«¥ was mixed with each substrate ¤final concentration © 2 µM for microsomes¥. A 200-µl aliquot of the microsomal mixture was transferred to a centrifuge tube and ultracentrifuged at 436,000 g for 120 min at 37ôC. After centrifugation, 20 µl of the upper layer was removed by siphoning and the concentration of the unchanged compound in the upper layer of the microsomal mixture was determined using LC-MS/MS. The remaining microsomal mixture was incubated for 120 min at 37ôC for determination of the total unchanged compound concentration by LC-MS/MS. The unbound fraction of the microsomal mixture ¤f u, mic ¥ was calculated using the following equation:
When correcting for the unbound fraction within the microsomal incubation mixture, CL uint, in vitro was defined as follows:
Biliary and urinary excretion of drugs in rats: Under isoflurane anesthesia, the bile duct was cannulated with a polyethylene catheter ¤PE-10; Becton Dickinson and Company, Franklin Lakes, NJ, USA¥ for bile collection, and the femoral vein was cannulated with a polyethylene catheter ¤PE-50; Becton Dickinson and Company¥ for drug administration. Each rat was placed in a Bollman cage ¤ML-30S, Sugiyama-gen Co., Ltd., Tokyo, Japan¥ and a screw-cap vial was used to collect urine. Drugs were administered intravenously at 1 mg/kg. Bile and urine samples were collected in pre-weighed test tubes for 24 h. All samples were stored at %30ôC until quantification. Bile and urine samples were deproteinized with 5 volumes of acetonitrile and centrifuged at 15,000 g for 5 min at 4ôC, and the resulting supernatant was analyzed by LC-MS/MS.
Pharmacokinetic experiments in rats: Under isoflurane anesthesia, the femoral artery was cannulated with a polyethylene catheter ¤PE-50¥ for blood sampling, and the femoral vein was cannulated with a polyethylene catheter ¤PE-50¥ for drug administration. Each rat was placed in a Bollman cage. Drugs were administered intravenously at 1 mg/kg. Blood samples were collected from the femoral artery at 0.1, 0.25, 0.5, 1, 2, 4, 6, and 24 h and centrifuged at 1500 g for 10 min at 4ôC to obtain plasma. All samples were stored at %30ôC until quantification. Plasma samples were deproteinized with 5 volumes of acetonitrile and centrifuged at 15,000 g for 5 min at 4ôC, and the resulting supernatant was analyzed by LC-MS/MS. Estimation of pharmacokinetic parameters in rats: Pharmacokinetic parameters were calculated via noncompartmental analysis. The area under the plasma concentration-time curve ¤AUCp¥ after intravenous dosing ¤1 mg/kg¥ in male SD rats was calculated using the trapezoidal rule with extrapolation to infinity, and total plasma clearance ¤CL t ¥ was estimated as dose/AUCp. The method for considering the contribution made by glucuronidation to total plasma clearance has been described previously.
8,17¥ Therefore, in vivo hepatic clearance by UGTs ¤CL H, UGT ¥ was calculated by correcting CL t with the fraction of glucuronide excreted in the urine and bile, assuming that the drugs were metabolized by rat hepatic UGTs. The hepatic availability ¤F H, UGT ¥ was calculated using the following equation:
where Q H represents the liver blood flow and % Gluc represents the percentage of excreted glucuronide. However, we were unable to accurately estimate F H, UGT for ezetimibe using Eq. 5 because the CL H, UGT of ezetimibe was liver blood flow limited. Therefore, CL H, UGT was taken to be 90% of the rat liver blood flow. The in vivo intrinsic clearance by UGTs ¤CL int, in vivo ¥ was calculated from the following equations using a dispersion model:
Estimation of scaling factors: Scaling factors, which indicate the discrepancy between CL int, in vivo and CL int, in vitro , were estimated using the following equation:
Overall scaling factors with and without correction for f u, mic were evaluated by the average fold error of the scaling factors. Thus:
Average fold error ¼ 10 1 n P log CL int; in vivo CL int; in vitro ð11Þ LC-MS/MS systems: Two LC-MS/MS systems were used. The first system comprised API3200 ¤Applied Biosystems, Foster, CA, USA¥ and LC-20AD ¤Shimadzu¥ series high-performance liquid chromatography ¤HPLC¥ systems fitted with LC-20AD pumps, an SCL-10AVP system controller, an SCL-20AC auto sampler, and a CTO-20AC column oven ¤Shimadzu, Kyoto, Japan¥. The second system comprised API2000 ¤Applied Biosystems¥ and HP1100 series HPLC ¤Agilent Technologies, Santa Clara, CA, USA¥ systems. The analytical conditions are described in Table 2 . Flow rates of 0.35 and 0.5 ml/min were used for the HP1100 ¤Agilent Technologies¥ and LC-20AD ¤Shimadzu¥ series HPLC systems, respectively. The ion chromatograms were integrated and quantified using Analyst software 1.4.1 ¤Applied Biosystems¥.
Data analysis: Kinetic parameters for the UGT reaction were calculated using GraphPad Prism 5 ¤GraphPad Software, Inc., La Jolla, CA, USA¥. The data for zidovudine glucuronidation were fitted to a Michaelis-Menten equation by the nonlinear least-squares method. Table 3 shows the CL int, in vitro and unbound CL int, in vitro ¤CL uint, in vitro ¥ values. CL int, in vitro values ranged from 0.10 ¤zidovudine¥ to 4500 ml/min/kg ¤ezetimibe¥; f u, mic values ranged from 0.29 ¤raloxifene¥ to 0.95 ¤gemfibrozil¥; and CL uint, in vitro values ranged from 0.11 ¤zidovudine¥ to 9600 ml/min/kg ¤ezetimibe¥.
Results

In vitro glucuronidation by UGTs in RLMs:
In vivo pharmacokinetic data: The in vivo pharmacokinetic data for the model compounds are summarized in Table 4 . The contribution of glucuronide was defined as the sum of the fractional urinary and biliary excretion data obtained for the glucuronide conjugate. Zidovudine showed the lowest amount of excreted glucuronide ¤12.0%¥ and gemfibrozil showed the highest ¤76.6%¥. The CL int, in vivo values determined using Eqs. 5®9 ranged from 5.7 ml/min/kg ¤zidovudine¥ to 9000 ml/min/kg ¤ezetimibe¥.
Comparison of in vivo and in vitro intrinsic clearances: The relationship between in vivo and in vitro intrinsic clearances is shown in Figure 1 . A good in vitroin vivo correlation was observed ¤regardless of the correction of CL int, in vitro using f u, mic ¥ for all compounds except zidovudine and telmisartan. The scaling factor values for the drugs are summarized in Table 5 . For 7/10 compounds, the scaling factor values obtained for CL uint, in vitro were closer to unity than those of CL int, in vitro . However, the scaling factor values obtained for CL uint, in vitro for zidovudine and telmisartan were 52 and 77, respectively.
The average fold error is an index of the in vitro-in vivo clearance correlation. A value of 1 indicates a perfect correlation, and larger or smaller values indicate a discrepancy between CL int, in vivo and CL int, in vitro . The average fold error values obtained for CL int, in vitro and CL uint, in vitro were 4.1 and 2.8, respectively.
In vitro glucuronidation of zidovudine by UGTs in RLMs in the presence or absence of 2% BSA: The glucuronidation activity of zidovudine in human liver microsomes ¤HLMs¥ is much lower than that observed where the total amount of glucuronide excreted was the sum of the fractional urinary and biliary excretion values for the glucuronide conjugates. Data for f p and R b ¤n © 2¥ and CL t and % Gluc ¤n © 2 or 3¥ are presented as the mean.
in vivo. 18¥ One reason for this discrepancy between CL int, in vitro and CL int, in vivo is competitive inhibition by unsaturated fatty acids; however, the addition of BSA to the incubation mixtures has been shown to reduce this competitive inhibition. 19¥ The discrepancy between CL int, in vivo and CL int, in vitro in the presence of BSA was approximately 10-fold less than in the absence of BSA. Therefore, to confirm the effect of BSA on zidovudine glucuronidation in RLMs, we determined CL int, in vitro both in the presence and absence of 2% BSA.
Vmax and Km were determined by fitting a MichaelisMenten model to the metabolite formation rate vs. substrate concentration data ¤Fig. 2, Table 6¥ . We found that CL int, in vitro in the presence of 2% BSA was approximately twice that in the absence of BSA; however, even in the presence of BSA, the large discrepancy between CL int, in vitro and CL int, in vivo persisted.
Discussion
Although several recent studies have attempted to predict hepatic clearance by UGTs in humans from in vitro data, few such studies have been conducted in rats, which are useful models in which to acquire hepatic clearance data and to evaluate the contribution of glucuronide for target compounds. The contribution of glucuronide to the elimination of drugs can be easily estimated in rats by measuring the glucuronide levels in the bile and urine after intravenous administration. However, conducting similar experiments in large animals, such as monkeys and dogs, is difficult, time-consuming, and costly. In this study, we used a rat model to investigate the relationship between CL int, in vitro and CL int, in vivo for ten drugs in an attempt to ascertain whether clearance via glucuronidation can be predicted based on results of an in vitro glucuronidation assay using liver microsomes.
In vitro microsomal data tend to underpredict glucuronidation clearance, 7,8¥ and in vitro glucuronidation activity is reported to be 10-to 30-fold lower than in vivo activity. 9¥ However, in the present study, the scaling factor values for CL int, in vivo to CL uint, in vitro observed for the examined compounds, with the exception of zidovudine and telmisartan, were less than 10 ¤Table 5¥, and those for 6/10 compounds were less than 2. This finding indicates a degree of consistency between CL int, in vivo and CL uint, in vitro , which we speculate is due to several factors. First, the drugs were incubated with RLMs activated by the membrane poreforming peptide alamethicin to increase in vitro glucuronidation activity. Because the UGT active site is located in the lumen of the endoplasmic reticulum, this membrane must be first disrupted to give the drugs access to the active site. 10¥ A previous study showed that alamethicin increases the glucuronidation of diclofenac by 5-fold or more. 13¥ In addition to the use of alamethicin, the drugs were also incubated in a Tris-based buffer containing Mg
2¦
. A synergistic effect of alamethicin and Mg 2¦ on glucuronidation was reported for acetaminophen, morphine, and estradiol, 11¥ and the use of a Tris-based buffer increased estradiol glucuronidation slightly more than a phosphate-based buffer did. 12¥ These studies suggest that optimized assay conditions may lead to in vitro glucuronidation levels comparable with those found in vivo. Second, f u, mic was incorporated into CL int, in vitro . f u, mic is an important factor for in vitro-in vivo correlation, because drugs bind nonspecifically to microsomal proteins resulting in an underestimation of in vitro intrinsic clearance.
5,20¥ Lipophilic drugs tend to bind to microsomal phospholipids. 21®23¥ Izumi et al. 14¥ also showed that f u, mic for the lipophilic compound troglitazone was approximately 0.01 and had a large impact on CL int, in vitro.
Here, values of the scaling factor between CL int, in vivo and CL int, in vitro became closer to unity when using the correction of f u, mic for 7/10 compounds. Notably, the value of f u, mic for the lipophilic compound raloxifene was the lowest of the ten examined compounds, and the discrepancy between CL int, in vitro and CL int, in vivo for raloxifene changed from greater than 2 to less than 2 following the correction of f u, mic . Finally, the glucuronides excreted into the bile and urine of rats after intravenous administration were measured to assess the contribution of glucuronidation to drug clearance. Previous studies have shown that diclofenac is metabolized via CYPs and UGTs in both rats and humans, 13¥ and that troglitazone is metabolized via CYPs, UGTs, and sulfotransferases. 14¥ Compounds containing polar groups typically have complicated metabolic pathways, and the contribution of glucuronidation must be considered to prevent overestimation of in vivo hepatic clearance based upon the activities of other metabolic enzymes.
A large discrepancy was noted between CL int, in vitro and CL int, in vivo for zidovudine and telmisartan, even when considering f u, mic . Rowland et al. 19¥ hypothesized that competitive inhibition by unsaturated fatty acids within human hepatic microsomes contributed to the underprediction of zidovudine glucuronidation. The same authors also found that the addition of BSA reduced the inhibitory effects of fatty acids, thereby rendering in vitro glucuronidation determinations based on incubation mixtures containing BSA comparable with the in vivo glucuronidation of zidovudine. Taking these previous findings into account, we also examined the impact of adding 2% BSA to the microsomal incubation mixture on the relationship between CL int, in vitro and CL int, in vivo ¤Fig. 2 and Table 6¥ . In the presence of 2% BSA, CL int, in vitro ¤0.23 mL/min/kg¥ was twice that found in the absence of BSA. However, the CL int, in vitro of zidovudine remained 25-fold less than the CL int, in vivo . Although the addition of 2% BSA to HLMs increased CL int, in vitro by 10-fold, 19¥ the increase was only 2-fold when 2% BSA was added to RLMs. These results indicate that effect of BSA on hepatic microsomal glucuronidation varies between species. Species differences in the sensitivity to BSA may result from the preparation methods used for rat and human liver microsomes. Human livers need to be frozen prior to preparation of microsomes due to pooling to adjust an individual enzymatic activity in microsomes to an average enzymatic activity, whereas microsomes from rat livers can be prepared without the freezing/thawing process. As UGT activities are affected by tissue freezing, which causes irreversible changes in ER membranes, 24¥ human liver microsomes may be more sensitive to BSA in vitro.
The discrepancy between CL int, in vitro and CL int, in vivo for telmisartan may be due to active uptake of the compound from the blood via the sinusoidal membrane. A previous study reported that Oatp isoforms are involved in the uptake of telmisartan into rat hepatocytes, and determined the Km ¤0.4 µM¥ and Vmax ¤371 pmol/min/10 6 cells¥ of telmisartan uptake into isolated rat hepatocytes. 25¥ Using the estimated Km and Vmax values, the uptake clearance was calculated as:
Uptake clearance ¼ Vmax Km Â Number of hepatocyte g liver Â liver weight kg body weight ¼ 4897 mL/ min/kg ð12Þ where the number of hepatocytes was 120 ' 10 6 /g liver, and the liver weight was 44 g liver/kg body weight. 26¥ The discrepancy between the uptake clearance of telmisartan and the overall in vivo intrinsic hepatic clearance observed in the present study ¤2000 ml/min/kg¥, which was estimated from the hepatic clearance of telmisartan, was closer to unity than the discrepancy between CL int, in vitro and CL int, in vivo . Uptake clearance has also been cited as the rate-determining process in the hepatic elimination of statins, with an in vitro uptake clearance similar to CL int, in vivo values. 27¥ Taken together, these findings suggest that the uptake of telmisartan is rate determining.
In summary, we successfully confirmed an in vitro-in vivo correlation for the rat hepatic glucuronidation of several compounds using alamethicin-activated liver microsomes, incorporating f u, mic into CL int, in vitro , and taking into account the contribution of glucuronidation toward clearance. These results provide important insights into the prediction of human hepatic glucuronidation from in vitro data.
